Welcome to Equity.Guru’s Roundtable where our writers weigh in on the pros and cons of a spotlight company, break out where they see value, and help you avoid public…
MYND.C
Whether you’re curious about taking a psychedelics investment trip or a tie-dyed-in-the-wool public market backer, psychedelics conferences are the best way to keep on top of industry advances and…
Interest in the psychedelic market is as high as Matt Gaetz and Joel Greenberg on a night out, but the accompanying FOMO has the potential to muddy the market,…
The psychedelics space is one of the hottest investment trips in the public markets today. Embryonic, wide open to possibility and with mounting scientific evidence of psychedelics’ healing properties,…
Another busy week in the psychedelic sector, with many smaller companies not always covered here at Equity Guru making news. Let’s start with the biggest players though. Mind Medicine…
MYND Life Sciences (MYND.C) announced they have signed a Letter of Intent (LOI) with Eyam Vaccines and Immunotherapies which outlines an Exclusive Licensing Agreement with respect to Eyam’s proprietary…
A different approach to MDD I’m big on companies having a unique approach to whatever they are doing. Many psychedelics companies are targetting depression but from a psychedelic-assisted therapy…